Alnylam Pharmaceuticals sees $1.6B to $1.725B TTR revenue in 2025 driven by AMVUTTRA expansion Alnylam Pharmaceuticals sees $1.6B to $1.725B TTR revenue in 2025 driven by AMVUTTRA expansion Post ContentalnyRead More You might also be interested in reading Tale of a crypto trader. February 14, 2025 In Mainstream ← Previous post Next post →